Advertisement
Advertisement
APUS
A
Apimeds Pharmaceuticals US, Inc.
1.78
USD-0.03
-1.66%
Jul 11, 13:25 UTC -4
Closed
After-Market
1.75
-0.03
-1.63%
Apimeds Pharmaceuticals US, Inc. Profile
About
Info & Links
CEO
Erik Emerson
Headquarters
HOPEWELL, NJ 08425, UNITED STATES
Industry
Sector
Website
Auditor
Kreit & Chiu CPA LLP
Share holders
--
Employees
2
Apimeds Pharmaceuticals US, Inc. Statistics
Valuation Measures
Market Capitalization2
20.27M
Enterprise Value
20.27M
Enterprise Value/EBITDA(ttm)
--
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
26.64%
Return on Assets(ttm)
--
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
--
Gross Profit(ttm)
0.00
EBITDA(ttm)3
0.00
Net Income Available to Common(ttm)
0.00
Diluted EPS(ttm)
--
Share Statistics
Beta (5Y Monthly)
--
52-Week Change
--
S&P 500 52-Week Change
11.16%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
--
Dividend Yield
0.00%
Float4
0.00
% Held by Insiders
--
% Held by Institutions
--
Balance Sheet
Total Cash(mrq)
--
Total Cash Per Share(mrq)
--
Total Debt(mrq)
--
Total Debt/Equity(mrq)
-49.62%
Current Ratio(mrq)
0.15%
Quick Ratio(mrq)
0.15%
Book Value Per Share(mrq)
-0.22
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.00
Free Cash Flow(ytd)
-20.30K
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement